The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis

被引:38
作者
Cao, Jinlong [1 ,2 ]
Yang, Xin [3 ]
Chen, Siyu [1 ,2 ]
Wang, Jirong [1 ,2 ]
Fan, Xinpeng [1 ,2 ]
Fu, Shengjun [1 ,2 ]
Yang, Li [1 ,2 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Urol, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China
[2] Key Lab Urol Dis Gansu Prov, Lanzhou 730000, Peoples R China
[3] Lanzhou Univ, Hosp 2, Reprod Med Ctr, Lanzhou 730000, Peoples R China
关键词
Tumor mutation burden; Immunotherapy; Immune checkpoint inhibitors; Meta-analysis; Bioinformatics; IMMUNE CHECKPOINT INHIBITORS; POTENTIAL BIOMARKER; CLINICAL-OUTCOMES; BLOCKADE; TORIPALIMAB; RECURRENT; THERAPY; SAFETY; TMB;
D O I
10.1016/j.tranon.2022.101375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the predictive efficacy of tumor mutation burden (TMB) as a potential biomarker for cancer patients treated with Immune checkpoint inhibitors (ICIs). Methods: We systematically searched PubMed, Cochrane Library, Embase and Web of Science for clinical studies (published between Jan 1, 2014 and Aug 30, 2021) comparing immunotherapy patients with high TMB to patients with low TMB. Our main endpoints were objective response rate (ORR), durable clinical benefit (DCB), overall survival (OS) and progress-free Survival (PFS). Moreover, we downloaded simple nucleotide variation (SNV) data of 33 major cancer types from the TCGA database as non-ICIs group, and compared the high TMB patients' OS between the non-ICIs group and meta-analysis results. Results: Of 10,450 identified studies, 41 were eligible and were included in our analysis (7713 participants). Compared with low TMB patients receiving ICIs, high TMB yielded a better ORR (RR = 2.73; 95% CI: 2.31-3.22; P = 0.043) and DCB (RR = 1.93; 95% CI: 1.64-2.28; P = 0.356), and a significantly increased OS (HR =0.24; 95% CI: 0.21-0.28; P < 0.001) and PFS (HR = 0.38; 95% CI: 0.34-0.42; P < 0.001). Furthermore, compared with non-ICIs group from the TCGA database, immunotherapy can improve OS in some cancer types with high TMB and better prognosis, including colorectal cancer, gastric cancer, lung cancer, melanoma and pan-cancer. Conclusion: TMB is a promising therapeutic and prognostic biomarker for immunotherapy, which indicates a better ORR, DCB, OS and PFS. If there is a standard for TMB assessment and cut-off, it could improve the management of different cancers.
引用
收藏
页数:14
相关论文
共 64 条
[1]   TMB or not TMB as a biomarker: That is the question [J].
Addeo, Alfredo ;
Friedlaender, Alex ;
Banna, Giuseppe L. ;
Weiss, Glen J. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163
[2]   Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer [J].
Alborelli, Ilaria ;
Leonards, Katharina ;
Rothschild, Sacha, I ;
Leuenberger, Laura P. ;
Prince, Spasenija Savic ;
Mertz, Kirsten D. ;
Poechtrager, Severin ;
Buess, Martin ;
Zippelius, Alfred ;
Laubli, Heinz ;
Haegele, Jasmin ;
Tolnay, Markus ;
Bubendorf, Lukas ;
Quagliata, Luca ;
Jermann, Philip .
JOURNAL OF PATHOLOGY, 2020, 250 (01) :19-29
[3]  
Araujo Daniel, 2021, JNCI CANCER SPECTRUM, V5, DOI [10.1093/jncics/pkaa122, DOI 10.1093/JNCICS/PKAA122]
[4]   Presumed Asymptomatic Carrier Transmission of COVID-19 [J].
Bai, Yan ;
Yao, Lingsheng ;
Wei, Tao ;
Tian, Fei ;
Jin, Dong-Yan ;
Chen, Lijuan ;
Wang, Meiyun .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14) :1406-1407
[5]   Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden [J].
Bomze, David ;
Ali, Omar Hasan ;
Bate, Andrew ;
Flatz, Lukas .
JAMA ONCOLOGY, 2019, 5 (11) :1633-1635
[6]   Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts [J].
Bortolomeazzi, Michele ;
Keddar, Mohamed Reda ;
Montorsi, Lucia ;
Acha-Sagredo, Amelia ;
Benedetti, Lorena ;
Temelkovski, Damjan ;
Choi, Subin ;
Petrov, Nedyalko ;
Todd, Katrina ;
Wai, Patty ;
Kohl, Johannes ;
Denner, Tamara ;
Nye, Emma ;
Goldstone, Robert ;
Ward, Sophia ;
Wilson, A. Gareth ;
Al Bakir, Maise ;
Swanton, Charles ;
John, Susan ;
Miles, James ;
Larijani, Banafshe ;
Kunene, Victoria ;
Fontana, Elisa ;
Arkenau, Hendrik-Tobias ;
Parker, J. Peter ;
Rodriguez-Justo, Manuel ;
Shiu, Kai-Keen ;
Spencer, Jo ;
Ciccarelli, D. Francesca .
GASTROENTEROLOGY, 2021, 161 (04) :1179-1193
[7]   The ever-increasing importance of cancer as a leading cause of premature death worldwide [J].
Bray, Freddie ;
Laversanne, Mathieu ;
Weiderpass, Elisabete ;
Soerjomataram, Isabelle .
CANCER, 2021, 127 (16) :3029-3030
[8]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426
[9]   Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer [J].
Chae, Young Kwang ;
Davis, Andrew A. ;
Raparia, Kirtee ;
Agte, Sarita ;
Pan, Alan ;
Mohindra, Nisha ;
Villaflor, Victoria ;
Giles, Francis .
CLINICAL LUNG CANCER, 2019, 20 (02) :88-+
[10]   Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients [J].
Chen, Xi ;
Fang, Liangjie ;
Zhu, Yanping ;
Bao, Zhang ;
Wang, Qing ;
Liu, Rong ;
Sun, Wenjia ;
Du, Haiwei ;
Lin, Jing ;
Yu, Bing ;
Chen, Songan ;
Zhou, Jianya ;
Zhou, Jianying .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) :3513-3524